Phase 2 N=136 A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell Malignancies
B-cell Malignancies · Cancer
Primary: Optimal Biologic Dose of MEDI-551 for Part A — 12 mg/Kg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=70 Clinical Evaluation of a Reusable Multifocal Optical Design in a Presbyopic Population Phase 2
Visual Acuity
Primary: Vision Scores — 42.2; 55.3; 52.4; 41.8 units on a scale
N/A N=54 The Role of Skin Care Regimen in Skin Health
Itching · Xerosis
Primary: Change in Total Clinical Score (TCS) Between the Final Visit and Baseline — -4; -2 score on a scale
N/A N=35 Light Therapy as Treatment for Fatigue in Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Primary: Change in Average Fatigue Severity Scale (FSS) Score — 45.824; 46.714 score on a scale
Phase 2 N=111 Study of Carboplatin/Paclitaxel With or Without Investigational Drug (CS-7017) in Subjects With Metastatic Non-small Cell Lung Cancer
Metastatic Non-small Cell Lung Cancer
Primary: Percentage of Participants With Progression-Free Survival at 18 Weeks Following Administration of Carboplatin/Paclitaxel With or Without CS-7017 in Chemotherapy-naïve…
Phase 1 N=23 Three Way Crossover Closed Loop Study With Xeris Glucagon
Type1diabetes
Primary: Percent of Time With Sensed Glucose < 70 mg/dl — 0; 8.3; 4.2 percentage 4 hrs post exercise on Day 1
Phase 4 N=32 Simulated Driving Performance, Daytime Sedation and Cognition in Healthy Volunteers Taking Gralise, Neurontin or Lyrica
Healthy
Primary: Change From Baseline in the "Standard Deviation of the Lateral Position" (SDLP) Measured on the Driving Simulator Between Gralise® and Neurontin® — 0.255; 0.395; 0.135…
Phase 3 N=175 Efficacy Assessment of Systematic Treatment With Folinic Acid and Thyroid Hormone on Psychomotor Development of Down Syndrome Young Children
Down Syndrome
Primary: GMDS (Griffiths Mental Development Scale) — 51.96; 51.27; 51.66; 51.67 developpement quotient
N/A N=200 Novel Biomarkers of Thrombotic Risk
Myocardial Infarction
Primary: Cardiovascular Event - Myocardial Infarction, Stroke, Death — 17; 6 Participants — p=0.007
Phase 3 N=397 Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
Psoriatic Arthritis
Primary: Number of Participants Achieving American College of Rheumatology 20 (ACR20) Response Criteria — 29; 51; 54; 15 Participants — p=0.0200
Phase 1 N=26 A Study of Various Formulations of LY900014 in Healthy Participants
Healthy
Primary: Pharmacokinetics (PK): Area Under The Concentration Curve (AUC 0-30mins) of Insulin Lispro — 245; 295; 251; 253 picomol per hours per liter (pmol*h/L)
Phase 3 N=416 Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With COPD Compared With Symbicort® Turbohaler®
COPD
Primary: Incidence of Post-baseline Newly Occurring or Worsening PCS (Potentially Clinically Significant) Clinical Chemistry Values — 0; 1; 0; 0 Count of Participants
N/A N=20 The DEB Pilot Study
Nutritional Physiological Phenomena · Obesity
Primary: Change From Baseline in Body Weight — -0.325; 0.230 kg — p==0.22
N/A N=138 Surgical Stress Markers for Postoperative Complications: a Prospective Study
Operative Procedures, Complications
Primary: Predictive Value of Postoperative Albumin Decrease in Terms of Surgical Stress and Postoperative Complications — 11.3 g/L
Phase 4 N=72 Extended Release Local Anesthetic for Postsurgical Pain After Posterior Colporrhaphy and Perineorrhaphy
Postoperative Pain
Primary: Postoperative Pain — 1.9; 1.3; 2.0; 1.9 mm